Showing 2,173 news articles about PrEP

Filters Content type: Editors' picks Topic: PrEP

Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP).

Access to healthcare

Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir

Editor's pick
Health GAP (Global Access Project)
27 July 2026
Injectable & long-acting PrEP

This drug could help end the HIV epidemic. Its rollout has hit speed bumps

Editor's pick
Science
27 July 2026
Access to healthcare

With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access

Editor's pick
The New York Times (requires free registration)
26 July 2026
PrEP policies & guidelines

South Africa: Motsoaledi defends limited rollout of lenacapavir amid challenges

Editor's pick
IOL
16 July 2026
Access to healthcare

Accelerating Access to Long-Acting HIV Medicines: A New Roadmap for Global Health

Editor's pick
Medicines Patent Pool
8 July 2026
Injectable & long-acting PrEP

Closer to home: taking long-acting HIV prevention into Zambia’s communities

Editor's pick
Unitaid
24 June 2026
Injectable & long-acting PrEP

Is Kenya’s lenacapavir rollout missing young women and girls?

Editor's pick
Devex (requires free registration)
22 June 2026
Injectable & long-acting PrEP

MSF launches global campaign demanding Gilead supply HIV prevention drug for $40 a year, everywhere

Editor's pick
MSF
22 June 2026
PrEP science

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Editor's pick
Gilead Sciences press release
17 June 2026
Injectable & long-acting PrEP

All you need to know about the jab that could dramatically reduce new HIV infections in South Africa

Editor's pick
Spotlight
6 June 2026
Injectable & long-acting PrEP

South Africa Helped Create Lenacapavir, Gilead Should Not Decide Who Gets It

Editor's pick
African Alliance
6 June 2026
Injectable & long-acting PrEP

Lenacapavir (Yeytuo) injected every six months approved for HIV prevention in Canada

Editor's pick
CATIE
6 June 2026
Injectable & long-acting PrEP

How Well Is Lenacapavir PrEP Working in the Real World? It’s Complicated.

Editor's pick
TheBodyPro
6 June 2026
Heterosexual men

HIV in South Africa: why rolling out a groundbreaking new shot will miss a critical group of men

Editor's pick
The Conversation
2 June 2026
Injectable & long-acting PrEP

A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It?

Editor's pick
The New York Times (requires free registration)
28 May 2026
Injectable & long-acting PrEP

Misinformation is coming for the anti-HIV jab. Let’s get ahead of it

Editor's pick
Bhekisisa
25 May 2026
PrEP science

Modelling study predicts PrEP efficacy driven by drug levels in cells: results in men match those previously reported in women

Editor's pick
i-Base
13 May 2026
PrEP programmes & uptake

Sharing is caring: HIV prevention pills are being shared in PrEP ‘Stokvels'

Editor's pick
Health-E News
13 May 2026
Injectable & long-acting PrEP

Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'

Editor's pick
FiercePharma
11 May 2026
Drug interactions & pharmacokinetics

New drug interaction PrEP website launched by Liverpool University

Editor's pick
i-Base
7 May 2026
Activism & civil society

For Michael Chancley Jr., PrEP advocacy is both a personal and professional matter

Editor's pick
Managed Healthcare Executive
4 May 2026
PrEP programmes & uptake

Transgender health in Australia: HIV drops by 94% as PrEP increases over 10 years

Editor's pick
i-Base
4 May 2026
Injectable & long-acting PrEP

Who controls South Africa’s lenacapavir rollout? Not South Africa

Editor's pick
Health-E News
24 April 2026
Injectable & long-acting PrEP

Only three new HIV cases on lenacapavir PrEP: updates from PURPOSE-1 and -2

Editor's pick
i-Base
23 April 2026